SUBSCRIBE
SUBSCRIBE

Phase 1

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
AstraZeneca PLC Continues Its Immuno-Oncology Roll, Durvalumab Gets Breathrough Designation for Bladder Cancer
February 17, 2016
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Armed with $50 Million from Google, Celgene and More, ARMO BioSciences Eyes Next-Gen Cancer Drug Combos
February 10, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
AstraZeneca PLC’s Immunotherapy Lung Cancer Combo Treatment Sees Breakthrough in Early Stage Trial
February 8, 2016
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Lab Criticized as ‘Slow to React’ in Bial’s Fatal Drug Trial
February 5, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
With Almost $200 Million in the Bank, WAVE Life Sciences Plans Six Clinical Programs in Three Years
January 29, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Akashi Halts DMD Clinical Trial, Third Company to Recently Have Problems With DMD Drug Trials
January 26, 2016
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Questions Remain as to What Caused the Bial Trial Tragedy in France
January 19, 2016
 · 
2 min read
Pfizer and Allergan Execs Emphasize Joint Company’s Pipeline, Hint Job Cuts Will Be Minimal
Drug Development
Biogen’s Promising Pipeline Underscores CEO’s High-Risk Strategy
January 18, 2016
 · 
4 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Drugmaker Unnamed as Botched Trial in France Leaves One Patient Brain Dead and Five Hospitalized
January 15, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Business
Booming Moderna Eyes Six Human Trials in 2016, Inks Deals with AstraZeneca PLC, Merck & Co. and Signed Huge Lease in Cambridge for R&D Growth
January 12, 2016
 · 
3 min read
Load More
PRESS RELEASES
Press Releases
ImmunoBrain Announces Nature Medicine Publication and Late-Breaking AAIC 2026 Presentation for IBC-Ab002 in Early Alzheimer’s Disease
July 14, 2026
 · 
5 min read
Press Releases
Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant
July 14, 2026
 · 
1 min read
Press Releases
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
July 14, 2026
 · 
5 min read
Press Releases
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
July 14, 2026
 · 
7 min read
Press Releases
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
July 14, 2026
 · 
6 min read
Press Releases
Axiom Biosciences Reports Positive Phase 1 Results for Investigational Stem Cell Therapy in Newborns with Severe Brain Injury
July 14, 2026
 · 
3 min read
Press Releases
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
July 14, 2026
 · 
8 min read
Press Releases
Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
July 13, 2026
 · 
9 min read
Press Releases
Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial
July 13, 2026
 · 
4 min read
Press Releases
Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting
July 13, 2026
 · 
2 min read
Press Releases
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
July 13, 2026
 · 
5 min read
Press Releases
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
July 13, 2026
 · 
9 min read
Press Releases
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
July 13, 2026
 · 
8 min read
Press Releases
New Phase 1 Data Show VNA-318 Mechanism of Action Translates to Humans, Supporting Potential to Address Medical Needs of People with Neurodegenerative Diseases
July 13, 2026
 · 
4 min read
Press Releases
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
July 9, 2026
 · 
7 min read
Press Releases
Astellas to Spotlight New Research for Geographic Atrophy at ASRS 2026 Annual Meeting
July 9, 2026
 · 
9 min read
Press Releases
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
July 9, 2026
 · 
7 min read
Press Releases
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
July 9, 2026
 · 
7 min read
Press Releases
Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in metastatic castration-resistant prostate cancer
July 9, 2026
 · 
6 min read
Press Releases
Kenai Therapeutics Announces Completion of Enrollment in Phase 1b/2a REPLACE™ Trial of RNDP-001 in Idiopathic Parkinson’s Disease
July 7, 2026
 · 
4 min read
Load More